EuroPCR

EuroPCR

Issue: July 2013
May 29, 2013
1 min read
Save

European experience validates MitraClip as nonsurgical option to reduce MR

Issue: July 2013
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

PARIS — Results from a large European, real-world registry have shown that the MitraClip leads to the reduction of significant mitral regurgitation and that usage of the device continues to expand in the continent.

The study, which was presented at EuroPCR by Ralph Stephan von Bardeleben, MD, of the University Medical Center Mainz, Germany, included the total number of European commercial MitraClip (Abbott Vascular) procedures (n=7,457), of which 7,226 were from a first MitraClip intervention and 231 were from a second.

Overall, patients had a mean age of 76 ± 10 years and 63% were male. Sixty-seven percent of patients had functional mitral regurgitation (MR), 23% had degenerative MR and 10% had a mixed etiology.

von Bardeleben reported that mean device time, defined as the time of insertion of the steerable guide catheter to the time the MitraClip delivery catheter was retracted into the steerable guide catheter, was 91 ± 61 minutes. A learning analysis revealed that during the 56 months from the first to last MitraClip procedure, there was a reduction in mean device time of 40 minutes (P<.001).

According to von Bardeleben, the device was successfully implanted in 95.8% of patients.

After the procedure, 94% of patients had a site-reported immediate post-interventional MR grade ≤2+ compared with less than 2% before the procedure.

“The MitraClip device provides a nonsurgical option for reduction of significant MR,” von Bardeleben concluded during his presentation. “Adoption of the MitraClip therapy as a nonsurgical treatment option in an underserved patient population [at] high risk or too high risk for surgery continues to expand, driven by procedural safety, positive patient outcomes and increasing, although mainly in Europe, physician experience.” – by Brian Ellis

For more information:

von Bardeleben RS. Novel catheter-based therapies of mitral regurgitation. Presented at: EuroPCR; May 21-24, 2013; Paris.

Disclosure: von Bardeleben has consulted for Bracco Milano, received honorarium from AstraZeneca, and has consulted for/received honorarium from Abbott Vascular, Philips Healthcare and Siemens Medical.